Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of hypocalcemia with telaprevir-based triple treatment in a case of genotype 1 chronic hepatitis C.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology - 1 May 2015

Şenateş Ebubekir, Çolak Yaşar, Yeşil Atakan, Tuncer İlyas

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypocalcemia

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Oligopeptides

Share to Polyethylene Glycols

Source

Identifiers

PMID: 26006210
DOI: 10.5152/tjg.2014.0083

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of hypocalcemia with telaprevir-based triple treatment in a case of genotype 1 chronic hepatitis C.PMID 26006210Read ↗

[Non-autoimmune hyperthyroidism].Semantic proximity Read ↗

A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Management and outcomes of side effects with focus on anaemia in patients with hepatitis C genotype 1 infection: the telaprevir early access program in patients from RomaniaSemantic proximity Read ↗

Telaprevir for the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C.Semantic proximity Read ↗

The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.Semantic proximity Read ↗

[Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].Semantic proximity Read ↗

[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy].Semantic proximity Read ↗

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

[Biochemical and pharmacological features of telaprevir].Semantic proximity Read ↗

[Hypercalcemia (with treatment)].Semantic proximity Read ↗

The pharmacological profile and the clinical efficacy of the world's 1st intravenous calcimimetics; etelcalcetide hydrochloride (Parsabiv®).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.